Pharma Sales

The regulatory body, which comes under the Department of Pharmaceuticals (DoP), took the decision to revise the prices of the formulations during the authority's 130th meeting on February 25

The common thread is backing grounded founders who are hands-on and have a relentless focus on execution

Despite challenges from a lower-margin product mix, Zydus Life benefitted from forex gains and a favourable tax rate, which led to a PAT beat, analysts said

The surge in Abbott India share price followed reports that JPMorgan, a New York-based financial services firm, raised its target price to Rs 31,500, up from Rs 30,000, signaling an upside of 12%

The Central Drugs Standard Control Organisation granted approval for the drug's use in combination with Durvalumab for the maintenance treatment of advanced or recurrent endometrial cancer in adults

Drug maker Lincoln Pharmaceuticals on Thursday said its consolidated net profit jumped by 24.51 per cent to Rs 23.67 crore in the April-June quarter of 2024-25 compared to Rs 19.01 crore in the year-ago quarter. Total income of the Ahmedabad-bnased company rose by 10 per cent to Rs 157.69 crore in the quarter under review from Rs 143.31 crore in the first quarter of 2023-24. Its operating profit (EBITDA) rose by 16.65 per cent to Rs 33.14 crore in the quarter from Rs 28.41 crore in Q1FY24. Both domestic and export operations have shown robust growth and the company is confident to enhance profitability and margins going forward, the company said in a statement. With focused growth strategies and business expansion plans for value added products and expanding to newer markets, the company is targeting revenue of Rs 750 crore in FY26, it said in the earnings statement. Lincoln Pharmaceuticals shares closed 0.95 per cent down at Rs 652.75 on BSE.

Ajanta Pharma on Tuesday said its consolidated profit after tax (PAT) increased 18 per cent year-on-year to Rs 246 crore for the June quarter, on account of robust sales across domestic and international markets. The drug firm had reported a profit after tax of Rs 208 crore in the April-June quarter of last fiscal. Revenue from operations rose to Rs 1,145 crore during the quarter under review as against Rs 1,021 crore in the year-go period, Ajanta Pharma said in a regulatory filing. The company said its India sales grew 10 per cent year-on-year to Rs 353 crore in the first quarter. The company's US sales grew 7 per cent to Rs 228 crore in the first quarter of the current fiscal. Shares of Ajanta Pharma ended 3.99 per cent up at Rs 2,524.35 apiece on the BSE.

The company's revenue from formulations increased by 17.2 per cent Y-o-Y to Rs 6,291 crore. Sequentially, it was up by 5.4 per cent from Rs 5,968 crore in Q2 FY24

MedPlus Health Services, a retail pharmacy and diagnostics chain in India, is set to elevate its "store generics" (in-house brand) to 50-60 per cent contribution to the firm's revenues in the next two to three years, drawing inspiration from the successful practices of US pharma retail giants like Walgreens and CVS. The concept of "store generics" involves a retail chain exclusively selling its own branded medications alongside innovator drugs. MedPlus currently witnesses around 12 per cent of its revenues from store generics. This strategic move follows the triumphant adoption of the "store generics" model in Telangana and subsequent expansions into Andhra Pradesh, Tamil Nadu, Karnataka, Maharashtra, West Bengal, and Odisha, Gangadi Madhukar Reddy, MD CEO of MedPlus said. Over the past six months, MedPlus has witnessed over 26.2 lakh customers saving a substantial Rs. 139.7 crores by opting for MedPlus brands, he said. To ensure the quality and efficacy of their medications, MedPl

Company reported lower-than-expected revenue after missing target in key segment

Sanofi shares trade at a 12 month forward price-to-earnings ratio of 11, a discount to AstraZeneca's 16 and global pharma index of 17, according to LSEG data

Data shows that in calendar year 2022, price driven growth rate has been 6 per cent; growth from new products has been 1.7 percent, while volume growth has been zero

The Gambian tragedy has raised uncomfortable questions about drug regulation in India. The Truth Pill is a depressing but eye-opening reality check of the regulatory landscape

Key antibiotic brands like Augmentin (GSK) and Clavam (Alkem) clocked 25 per cent and 29 percent growth, respectively, in November, the data showed

In a Q&A, Nandini Piramal, chairperson of the firm, says the company currently sees great scope in expanding and organically growing the OTC business, and wants to build more consumer focused brands

Softbank-backed B2B e-commerce firm Udaan has started delivering stocks to pharmacies four times a day across six cities and plans to scale up the service to other places after six to eight months, the company said on Thursday. The 4X4 delivery service' has been rolled out after a pilot programme and receiving extensive feedback from pharmacies in select cities, which required enhanced delivery capabilities. During the pilot phase, the business witnessed a 45 per cent rise in orders in the select cities. "As part of the new service offering, Udaan will provide medicine delivery to pharmacies every 4-hour with 4 delivery slot options in a day to order medicines across six cities - Kolkata, Jaipur, Indore, Ahmedabad, Bengaluru and Pune. Udaan plans to scale the '4X4 delivery service' to more cities and towns in the next 6-8 months," the company said in a statement. Udaan Business head for Pharma Category Sanjay Sharma said the company will leverage for the convenience and faster ...

Company founded by 4 IIT graduates will use money to expand its presence and for improving technology

In December 2019 the decision was revised to allow sale of land to private entities as well through a competitive bidding process

The 2022 revision of the NLEM came after seven years. Most drugs that have been now brought into the NLEM include anti-infectives, anti-diabetics, anesthetics, etc

But exports to stay under the weather; credit outlook remains stable